Table 2 Intention-to-treat (ITT) and per-protocol (PP) analysis of the Efficacy of the Sufficient Improvementa of Reflux symptoms between the Two Groups
| Â | Standard-dose groupb | High-dose groupc | P-value | ||
|---|---|---|---|---|---|
n/N (%) | 95% CI | n/N (%) | 95% CI | ||
ITT analysis | |||||
 Total symptoms | |||||
  All gender | 27/40 (67.5) | 60.0–75.0 | 39/44 (88.6) | 83.8–93.4 | 0.018 |
  Male | 7/12 (58.3) | 43.4–73.2 | 14/15 (93.3) | 86.6–100.0 | 0.060 |
  Female | 20/28 (71.4) | 62.7–80.1 | 25/29 (86.2) | 79.7–92.7 | 0.171 |
 Typical symptomsd | |||||
  All gender | 24/29 (82.8) | 75.7–89.9 | 33/33 (100.0) | 100.0–100.0 | 0.018 |
  Male | 6/8 (75.0) | 58.6–91.4 | 10/10 (100.0) | 100.0–100.0 | 0.183 |
  Female | 18/21 (85.7) | 77.9–93.5 | 23/23 (100.0) | 100.0–100.0 | 0.100 |
 Atypical symptomse | |||||
  All gender | 20/31 (64.5) | 55.8–73.2 | 31/39 (79.5) | 72.9–86.1 | 0.162 |
  Male | 5/9 (55.6) | 38.0–73.2 | 14/15 (93.3) | 86.6–100.0 | 0.047 |
  Female | 15/22 (68.2) | 58.0–78.4 | 17/24 (70.8) | 61.3–80.3 | 0.845 |
PP analysis | |||||
 Total symptoms | |||||
  All gender | 24/35 (68.6) | 60.6–76.6 | 35/38 (92.1) | 87.7–96.5 | 0.011 |
  Male | 7/11 (63.6) | 48.4–78.8 | 13/14 (92.9) | 85.8–100.0 | 0.133 |
  Female | 17/24 (70.8) | 61.3–80.3 | 22/24 (91.7) | 87.1–98.7 | 0.137 |
 Typical symptomsd | |||||
  All gender | 21/25 (84.0) | 76.5–91.5 | 29/29 (100.0) | 100.0–100.0 | 0.040 |
  Male | 6/8 (75.0) | 58.6–91.4 | 10/10 (100.0) | 100.0–100.0 | 0.183 |
  Female | 15/17 (88.2) | 80.1–96.3 | 19/19 (100.0) | 100.0–100.0 | 0.216 |
 Atypical symptomse | |||||
  All gender | 17/27 (63.0) | 53.5–72.5 | 28/34 (82.4) | 75.8–89.0 | 0.087 |
  Male | 5/8 (62.5) | 44.2–80.8 | 13/14 (92.9) | 85.8–100.0 | 0.117 |
  Female | 12/19 (63.2) | 51.8–74.6 | 15/20 (75.0) | 65.1–84.9 | 0.423 |